These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 17663001)

  • 1. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
    J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
    Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
    Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
    Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
    Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
    Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
    J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.
    Nakamura Y; Yasuoka H; Tsujimoto M; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Breast Cancer Res Treat; 2005 May; 91(2):125-32. PubMed ID: 15868440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
    Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
    Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
    Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Hara Y; Kobayashi S; Iwase H
    Breast Cancer Res Treat; 2005 Nov; 94(1):11-6. PubMed ID: 16172792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
    Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
    Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical implications of MMP-11 and CK-20 expression in human breast cancer.
    Cheng CW; Yu JC; Wang HW; Huang CS; Shieh JC; Fu YP; Chang CW; Wu PE; Shen CY
    Clin Chim Acta; 2010 Feb; 411(3-4):234-41. PubMed ID: 19914229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
    Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
    Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
    Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
    Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
    Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay.
    Bièche I; Noguès C; Paradis V; Olivi M; Bedossa P; Lidereau R; Vidaud M
    Clin Cancer Res; 2000 Feb; 6(2):452-9. PubMed ID: 10690523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.